3 ms·
The development of an oncologic (from preclinical through clinical) typically costs more like 10-20 million dollars. I'm not sure where you got 5 billion from.
by dnautics 12y ago
The development of an oncologic (from preclinical through clinical) typically costs more like 10-20 million dollars. I'm not sure where you got 5 billion from. Now, pharma companies inflate the cost of a single drug by creatively rolling in a lot of failures as the 'cost of getting there', sometimes warranted, often maybe not so much. As it is big pharma spends more money on advertising than R&D anyways.
Generics manufacturers, incidentally, do just fine, and I can imagine a more sustainable model of pharmacological research where a generics builds up an R&D war chest and periodically discharges it on new research.
The hard part is the political intractability of getting big pharma to let go of 20% margins and settle for 5% margins.
Edit: error, 10mm only for preclinical, not both.
- sliverstorm 12y agoAt 5% margins, I would think there are a lot of better places to invest your money.
- jonlucc 12y ago10-20 million is nowhere close. A single moderate size monkey study costs around $900,000 at a CRO (because most pharma companies don't have their own NHP facilities). This paper [1] places it between $500 million and $2 billion, but it apparently uses a source of self-reported data from the industry. Phase 3 studies are often in the hundreds of millions of dollars range, because they have to basically pay for a thousand or more subjects to have Rx-quality drug and intermittent medical care for several years. [1] http://content.healthaffairs.org/content/25/2/420 http://content.healthaffairs.org/content/25/2/420
- dnautics 12y agoSorry I made a mistake. ~10mm for preclinical ~100mm for clinical. (I'm used to thinking only of the 10mm number because I only intend to do preclinical stuff) Oncologics are individually cheaper to develop because the sample size can be smaller for efficacy studies but are reported as higher because there are reportedly more failures. I'm not sure how to judge these things though... How much can be saved by working smarter not harder?
- anigbrowl 12y agoIt seems to me that your argument relies very heavily on survivor bias. Expensive failures are an entirely necessary part of the research process. I picked $5 billion because I think that's the minimum cost of developing a general broad spectrum anticancer drug, which seems like the overarching goal. I should have distinguished between that and the more limited purpose of developing 9DS in particular. Generics manufacturers, incidentally, do just fine Well obviously, they are in the business of manufacturing something already proven to work. Some of them do move towards doing their own R&D but they have to deal with the same success:failure ratios as existing pharma companies. I feel like you think bi pharma just wants huge margins out of greed and that the failures or research that goes nowhere is somehow costless. There's not only a direct cost of losses incurred on a drug that doesn't work out at the clinical trial stage, there's also the opportunity cost of options foregone which might have brought successful therapies to market faster. I don't own any pharma shares and am not a particular fan of the industry, but it seems to me that your criticisms involve a huge amount of hindsight bias. If it was as easy as you suggest the market should be awash in pharama startups. Instead, the number of biotech startups (a reasonable proxy, though not an exact mapping) is about half of what it was a decade ago due to a dearth of funding: http://www.xconomy.com/national/2013/11/18/biotech-startup-class-2013-dont-worry-short-list/ http://www.xconomy.com/national/2013/11/18/biotech-startup-c... I suggest to you that this to a large extent reflects the risk in this sector.
- dnautics 12y agoA biotech startup has one similar thing to a hitech startup - and that's that the predominant exit strategy is to 'get bought out by a big player'. In my opinion, the market isn't awash in pharma startups, because of three factors. 1) high capital costs. 2) most pharma startups are started by professors; the selection process for professors is in many ways orthogonal to 'success in developing pharmaceuticals'. 3) Labor talent. Because of the now about decades-long (over/mal)investment in STEM, there has been a glut of PhDs with questionable qualifications, that flood the labor market. I don't generally argue the 'greed drives things' argument. No, pharma companies don't want big margins necessarily out of greed, but the momentum, machine, and in certain cases legal infrastructure (requirements of companies to provide returns to investors, etc) align in such a way that dislodging big pharma from its position of legal entitlement is politically intractable, because they will fight for it, whether dominantly greed-motivated or not.
- tzs 12y ago> Generics manufacturers, incidentally, do just fine, and I can imagine a more sustainable model of pharmacological research where a generics builds up an R&D war chest and periodically discharges it on new research. Why would the generics manufacturers want to do that instead of treating that money as profits for the shareholders? As long as they can keep their manufacturing facilities humming along at capacity cranking out the generics we already have for numerous chronic conditions, do they really care if new generics are being developed?
- dnautics 12y agoReally? http://www.equitymaster.com/detail.asp?date=09/04/1999&story=1&title=Cipla-in-high-gear-ups-RD-budget http://www.equitymaster.com/detail.asp?date=09/04/1999&story... For example.